A Randomized, Double-Blind, Placebo-Controlled Two Dose-Arm Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10%, (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer's Disease
ID Number 08-1326Principal Investigator(s)
Hillel T. Grossman
Department(s) or Division(s)
The purpose of this study is to determine whether IGIV, 10% treatment either at a dose of 400 mg/kg body weight (BW)/2 weeks or200 mg/ kg BW/2 weeks for 9 months results in a significantly slower rate of decline of dementia symptoms in subjects with mild-to-moderate Alzheimer’s Disease (AD) as compared to placebo, as measured by the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-Cog) and the Alzheimer’s Disease Cooperative Study (ADCS)-Clinical Global Impression of Change (ADCS-CGIC).
Recruiting Patients: Yes